Keywords: |
adult; treatment outcome; aged; disease-free survival; middle aged; survival rate; clinical trial; mortality; doxorubicin; dose response; paclitaxel; disease free survival; chemotherapy, adjuvant; cancer staging; methodology; antineoplastic agent; lymph nodes; neoplasm staging; controlled clinical trial; mastectomy; randomized controlled trial; antineoplastic combined chemotherapy protocols; drug administration schedule; cyclophosphamide; pathology; dose-response relationship, drug; breast neoplasms; cancer invasion; randomized controlled trials; adjuvant chemotherapy; breast tumor; lymph node; neoplasm invasiveness; maximum tolerated dose; drug administration; humans; prognosis; human; female; article
|